Communiqués Axsome Therapeutics, Inc. Boerse Muenchen

Actions

19X

US05464T1043

Produits pharmaceutiques

Marché Fermé - Boerse Muenchen 22:43:56 02/10/2026			Varia. 5j.	Varia. 1 janv.
158,15 ^EUR	-1,77%		-6,31%	+25,15%

29/09	Axsome Therapeutics, Inc. : Deutsche Bank Securities favorable sur le dossier	ZM
25/09	Auvelity d'Axsome poursuit sa bonne dynamique de lancement, selon Mizuho	MT

Communiqués

21/09	Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day	GL
21/09	Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day	AQ
17/09	Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026	GL
17/09	Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026	AQ
02/09	Axsome Therapeutics to Participate in Upcoming Investor Conferences	GL
31/08	Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation	GL
10/08	Axsome: Q2 Earnings Snapshot	AQ
10/08	Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update	GL
15/07	Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy	GL
14/07	Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10	GL
07/07	Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)	GL
07/07	Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)	AQ
26/06	Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)	GL
18/06	Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month	GL
15/06	Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026	GL
05/06	Axsome Therapeutics Presents New SYMBRAVO Data at the Americal Headache Society 68th Annual Scientific Meeting	AQ
04/06	Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting	GL
03/06	Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation	GL
01/06	Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month	GL
27/05	Axsome Therapeutics to Participate in Upcoming Investor Conferences	GL
26/05	Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting	GL
26/05	Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting	AQ
07/05	Axsome Therapeutics Recognizes Mental Health Month	GL
07/05	Axsome Therapeutics Recognizes Mental Health Month	AQ
05/05	Axsome Therapeutics to Participate in Upcoming Investor Conferences	GL